« Return to News | CROs/Service Providers

QED Clinical Services to launch OrphanReach drug development division

Thursday, August 30, 2012 11:13 AM

QED Clinical Services, a global niche CRO operating, is launching OrphanReach, a division to develop drugs in rare disease areas.

OrphanReach will capitalize on QED’s global infrastructure, while employing a flexible, adaptive approach, providing a good fit with orphan drug development needs.

"We can clearly see a strong industry trend for orphan drug development activities,” said Thomas Ogorka, CEO of QED. “Any company developing drugs for orphan indications needs a service provider who can not only offer tailor-made solutions in a very effective and attentive way, but also has access to these rare patient populations no matter where in the world.”

Ogorka continued, “QED's new OrphanReach division offers our sponsors exactly that: a lean management structure with excellent client attention and at the same time the global reach element which one would have thought only the largest CROs can provide. QED is a good example that an innovative operational model can work perfectly well in combination with niche areas like the development of orphan and rare disease drugs thus providing sponsors with a powerful CRO alternative."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.